DxPx Investors Conference Defies the Crisis With a New Concept

Largest investor partnering conference for diagnostics, personalized medicine and research tools from November 17th to 21st

Over 150 investors and more than 350 registrations from over 20 countries

DUSSELDORF, Germany – Innovative diagnostic solutions play an essential role in coping with the corona pandemic. In order to better meet current and future challenges, DxPx 2020, Europe’s largest international partnering conference for diagnostics, digital health, regenerative medicine and research tools offers the ideal network platform for startups, companies and investors.

The planned hybrid event concept had to be adjusted due to the increasing number of COVID-19 infections. To this end, the DxPx has been extended and will now take place for the first time as a digital five-day partnering conference from Tuesday 17thto Saturday 21st of November. With an adapted digital concept, investment opportunities, M&A and license options and R&D partnerships between entrepreneurs and investors can still be evaluated in pre-scheduled one-to-one meetings.

“Right now, it’s extremely important to increasingly promote innovative new solutions for managing the crisis. Therefore, we’re passing on the savings from the now purely digital event one-to-one to startups and are offering a reduced rate of €199 for the entire five days with over 150 investors. As the organizers, we’ll also be offering a prize of €5.000 for the best pitch in order to set an example in times of crises,” explains Dr. Mirko Stange as the initiator of the DxPx.

Christoph Brandenberger, Managing Director at the US investment bank Brown Gibbons Lang & Company and together with Roche Diagnostics, one of the two gold sponsors of DxPx: “We’re looking forward to participating again in the DxPx conference despite of all the challenges during this year. The conference offers an ideal platform and shows how important such events are, especially in times of COVID. This is also shown by the already more than 100 applications for the DxPx Award – a significant increase compared to the previous year.” The registration period has been extended to November 6th.

For the first time, DxPx 2020 also offers the opportunity for companies to present their business to over 40 investors from Asia with the China Forum in addition to investor partnering.

Journalists can register via info@dxpx-conference.com

Oliver Dick

Oliver brings 30+ years of experience in the life sciences industry, has worked in pharma, biotechnology and in vitro diagnostics. His areas of expertise fall under Supply Chain Management, Planning, Production, QC, QA, Engineering, Technology Transfer and Process Improvement. Amongst his vast experience, Oliver held functions such as Vice President of Global Manufacturing at QIAGEN, Chief Operating Officer at Miltenyi Biotec or Chief Operating Office of Resolve Biosciences. He demonstrated exceptional leadership and expertise in driving manufacturing excellence on a global scale.

Oliver has a proven ability to streamline processes, optimize production efficiency, and foster a culture of innovation. He was responsible for strategy development, scaling, cost control and quality and was part of multiple M&A projects and transfer of many new products from acquisition or own development. Today Oliver offers his expertise mainly through his own Consultancy Service Company ODICON.


Christoph Brandenberger is a Managing Director at BGL and a leader in the firm’s Diagnostics, Research Tools & Medical Devices investment banking group. He has more than 20 years of experience in all aspects of mergers and acquisitions, commercialization and partnering agreements, and private placements.

A native of Austria and fluent in German, Christoph’s investment banking experience, coupled with his background in international business, has made him a sought-after advisor in both the domestic and international healthcare markets.

Prior to joining BGL, Christoph served as managing director for Healthios Capital Markets, LLC. Christoph started his career as a financial analyst for Bank of America Securities.


John Riddle

John Riddle is a Managing Director and member of the BGL Executive Committee. He has more than 30 years of investment banking and capital markets experience, advising clients across a broad spectrum of mergers and acquisitions, capital markets activities, and strategic assignments.

John leads BGL’s advisory activities in the Healthcare & Life Sciences investment banking group, which comprises both corporate investment banking and real estate capital markets capabilities. Together with his team, John maintains an ongoing coverage effort with broad activity across several sectors, including health facilities, physician services, and ancillary providers; diagnostics and research tools; medical device and products; and select healthcare technology verticals, including payor services, data analytics, and clinical automation.


Dr. Mirko Stange

Born in Bremen, Germany in 1974, Dr. Mirko Stange is a diagnostics and life sciences expert with a proven track record in turning around and commercializing innovations. He possesses extensive executive management experience, having led diagnostics and biotech startups, as well as developing and conducting consulting products. Following the completion of his Ph.D. in Biochemistry and Biophysics at the University of North Carolina at Chapel Hill, Dr. Stange began his career in 2004 at the strategy consultancy McKinsey. Subsequently, he worked with the turnaround-specialized advisory firm Droege & Comp., primarily serving clients from the pharma and chemistry industry in Germany and Switzerland.

In 2008, he founded an independent Life Sciences consultancy in Germany where, to date, he leads and directs a team of international experts. This team identifies and funds SMEs with high potential for national and international leverage. In addition to his over ten years of experience in independent corporate finance and management consulting, Mirko Stange provides interim management services to selected clients. To date, three companies co-founded and managed/advised by Dr. Stange have been successfully exited. Leveraging his scientific background, he is also a named inventor on several granted and pending patents.


FName LName

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.